TOKYO and MENLO PARK, Calif., Jan. 8, 2024 /PRNewswire/ -- Taiho Pharmaceutical Co., Ltd. and Taiho Ventures, LLC, a strategic corporate venture capital arm of Taiho Pharmaceutical, announced today that Taiho Ventures has increased its investment pool by $100 million from $300 million to $400 million.
Taiho Pharma`s Lytgobi (futibatinib) Receives Approval in Europe
Taiho Pharmaceutical Co., Ltd. (Taiho Pharmaceutical) and Phost’in Therapeutics SAS (Phost’in) today announced that the two companies have entered into an option and license agreement through which Taiho Pharmaceutical will obtain option rights to inlicense PhOx430, a First-in-Class small molecule targeting GnT-V (Nacetylglucosaminyltransferase-V).
PRINCETON, N.J., Aug. 2, 2023 /PRNewswire/ -- Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved LONSURF® (trifluridine/tipiracil) as a single agent or in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.
Taiho`s Lytgobi (futibatinib) Receives Approval in Europe
U.S. Food and Drug Administration Accepts for Priority Review Taiho Oncology's Supplemental New Drug Application for the Use of Trifluridine/Tipiracil (LONSURF®) in Combination With Bevacizumab for Refractory Metastatic Colorectal Cancer (mCRC)
Taiho Pharmaceutical Co., Ltd. announced today that the Japanese Ministry of Health, Labour and Welfare has approved an additional indication of postoperative adjuvant chemotherapy for hormone receptor-positive and HER2-negative breast cancer at high risk of recurrence for its oral anticancer agent TS-1 combination capsules T20/T25, TS-1 combination granules T20/T25, and TS-1 combination OD tablets T20/T25 (generic name: tegafur, gimeracil, oteracil potassium, hereafter “TS-1”).
PARIS--(BUSINESS WIRE)--Servier, Taiho Oncology, Inc., and Taiho Pharmaceutical Co., Ltd., announced today that the investigational combination of trifluridine/tipiracil plus bevacizumab showed a statistically significant improvement in the primary endpoint of overall survival (OS) compared to trifluridine/tipiracil alone in a Phase III clinical trial of participants with refractory metastatic colorectal cancer (mCRC) following two chemotherapy regimens.
Cullinan Oncology receives upfront cash payment of $275 million, with potential to receive up to an additional $130 million in regulatory-based milestone payments Taiho obtains exclusive global...